Xiamen Amoytop Biotech Co., Ltd. (688278.SS)
CNY 74.3
(-1.72%)
CNY 74.3
(-1.72%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.1 Billion CNY | 37.55% |
| 2022 | 1.52 Billion CNY | 34.86% |
| 2021 | 1.13 Billion CNY | 42.61% |
| 2020 | 793.93 Million CNY | 8.81% |
| 2019 | 729.66 Million CNY | 62.77% |
| 2018 | 448.28 Million CNY | 38.75% |
| 2017 | 323.08 Million CNY | 15.23% |
| 2016 | 280.37 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 545.3 Million CNY | -14.87% |
| 2024 Q3 | 764.89 Million CNY | 19.3% |
| 2024 Q2 | 641.17 Million CNY | 17.58% |
| 2023 Q4 | 640.53 Million CNY | 15.16% |
| 2023 FY | 2.1 Billion CNY | 37.55% |
| 2023 Q3 | 556.21 Million CNY | 14.86% |
| 2023 Q1 | 419.3 Million CNY | 9.28% |
| 2023 Q2 | 484.27 Million CNY | 15.49% |
| 2022 Q1 | 345 Million CNY | 7.0% |
| 2022 FY | 1.52 Billion CNY | 34.86% |
| 2022 Q4 | 383.7 Million CNY | -10.42% |
| 2022 Q3 | 428.32 Million CNY | 15.81% |
| 2022 Q2 | 369.85 Million CNY | 7.2% |
| 2021 Q3 | 340.55 Million CNY | 34.17% |
| 2021 Q4 | 322.43 Million CNY | -5.32% |
| 2021 Q2 | 253.82 Million CNY | 17.84% |
| 2021 Q1 | 215.41 Million CNY | -7.71% |
| 2021 FY | 1.13 Billion CNY | 42.61% |
| 2020 Q4 | 233.41 Million CNY | 16.15% |
| 2020 Q1 | 187.5 Million CNY | -6.99% |
| 2020 Q2 | 172.05 Million CNY | -8.24% |
| 2020 Q3 | 200.96 Million CNY | 16.8% |
| 2020 FY | 793.93 Million CNY | 8.81% |
| 2019 Q1 | 146.45 Million CNY | 6.65% |
| 2019 FY | 729.66 Million CNY | 62.77% |
| 2019 Q4 | 201.58 Million CNY | -3.74% |
| 2019 Q3 | 209.4 Million CNY | 21.59% |
| 2019 Q2 | 172.21 Million CNY | 17.59% |
| 2018 Q3 | 140.47 Million CNY | 0.0% |
| 2018 Q4 | 137.32 Million CNY | -2.24% |
| 2018 FY | 448.28 Million CNY | 38.75% |
| 2017 FY | 323.08 Million CNY | 15.23% |
| 2016 FY | 280.37 Million CNY | 0.0% |